Manufacturing plant expansion
German pharmaceutical firm Fresenius Kabi is expanding its pharmaceutical manufacturing facility in Wilson, North Carolina.
On completion, the facility is expected to increase its manufacturing capacity for generic drugs in ready-to-administer pre-filled syringes. Fresenius Kabi is investing more than $100m in the expansion.
Announced in November 2017, the expansion will create 445 new jobs in the region. It is Fresenius Kabi’s second project in North Carolina, following a previous announcement of plans to construct a new manufacturing facility in Wilson, which will produce products for hospitals and clinics across the US and Canada.
The Wilson facility is one of the country’s largest biotechnology centres. Its expansion will enable Fresenius Kabi to invest in the development of products and operations to meet growing demand. It will modernise the facility into a global centre for prefilled syringe production.
The existing manufacturing facility employs more than 100 people in various roles. The expansion will increase the employee count to more than 500, adding jobs in various functions such as production specialists, engineers, scientists and managers.
Manufacturing contributes 22% to the economic output of North Carolina. The new project will enable North Carolina to retain its position in the manufacturing and life sciences sectors. It is estimated to boost the state’s economy by $853m.
The Economic Investment Committee of North Carolina state has approved a 12-year job development investment grant (JDIG) for the project. Fresenius Kabi will create 445 jobs over five years as part of the terms of the grant. The company will receive a reimbursement of $7.2m over 12 years as a benefit for the tax revenues generated by the new jobs it creates.
The North Carolina Department of Commerce and the Economic Development Partnership, the North Carolina General Assembly, the North Carolina Community College System, the North Carolina Biotechnology Center, Wilson County and the Wilson Economic Development Council collaborated with the state government to provide the grant.
Fresenius Kabi acquired the Wilson manufacturing plant from American medical technology company Becton Dickinson and Company (BD) in January 2016. The facility was part of BD’s Rx business.
Approved by the US Food and Drug Administration (FDA) in 2012, the facility is equipped with state-of-the-art manufacturing and packaging technologies. It develops various drugs in ready-to-administer pre-filled syringes.
Headquartered in Bad Homburg, Germany, Fresenius Kabi is a healthcare company involved in the development of medical devices, life-saving technologies and clinical nutrition products.
The US headquarters of the firm is situated at Lake Zurich, Illinois, and employs 1,500 people. The company operates manufacturing sites at Bensenville, Skokie, Lake Zurich and Melrose Park. It has a total workforce of more than 3,000 in the US.
Fresenius Kabi also has production plants in New York, Pennsylvania, Puerto Rico and the Dominican Republic.
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Arranta Bio is constructing a new multi-product, commercial-ready manufacturing facility in Watertown, Massachusetts, US. Watertown facility will be used for…
Berkshire Sterile Manufacturing (BSM) is expanding its manufacturing facility in Lee, Massachusetts (MA), US. The company began preparations for the…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…